Hanyi Zhang

Hanyi Zhang

Auto-generated profile, based on publicly available information

Hanyi Zhang

Department of Dermatology, XiangYa Hospital, Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2023 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
JGJia Guo
Jia Guo
HZHanyi Zhang
Hanyi Zhang
WLWenrui Lin
Wenrui Lin
LLLixia Lu
Lixia Lu
HZHanyi Zhang
Hanyi Zhang
XCXiang Chen
Xiang Chen
Psoriasis is a common, chronic, and inflammatory skin disease with a high burden on individuals, health systems, and society worldwide. With the immunological pathologies and pathogenesis of psoriasis becoming gradually revealed, the therapeutic approaches for this disease have gained revolutionary progress. Nevertheless, the mechanisms of less common forms of psoriasis remain elusive. Furthermore, severe adverse effects and the recurrence of disease upon treatment cessation should be noted and addressed during the treatment, which, however, has been rarely explored with the integration of preliminary findings. Therefore, it is crucial to have a comprehensive understanding of the mechanisms behind psoriasis pathogenesis, which might offer new insights for research and lead to more substantive progress in therapeutic approaches and expand clinical options for psoriasis treatment. In this review, we looked to briefly introduce the epidemiology, clinical subtypes, pathophysiology, and comorbidities of psoriasis and systematically discuss the signaling pathways involving extracellular cytokines and intracellular transmission, as well as the cross-talk between them. In the discussion, we also paid more attention to the potential metabolic and epigenetic mechanisms of psoriasis and the molecular mechanistic cascades related to its comorbidities. This review also outlined current treatment for psoriasis, especially targeted therapies and novel therapeutic strategies, as well as the potential mechanism of disease recurrence.

22 January 2024 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
JGJia Guo
Jia Guo
HZHanyi Zhang
Hanyi Zhang
WLWenrui Lin
Wenrui Lin
LLLixia Lu
Lixia Lu
JSJuan Su
Juan Su
XCXiang Chen
Xiang Chen

15 April 2026 in iScience
Verified
Journal Article
Open access
HZHanyi Zhang
Hanyi Zhang
WLWanyao Liu
Wanyao Liu
YXYi Xiao
Yi Xiao
ZLZhongling Luo
Zhongling Luo
JSJuan Su
Juan Su
Immune-mediated inflammatory skin diseases (IMSDs), including atopic dermatitis (AD), psoriasis (Pso), acne vulgaris (AV), and alopecia areata (AA), impose substantial but uneven global burdens. Using Global Burden of Disease 2021 estimates, we quantified incidence, prevalence, and disability-adjusted life years (DALYs) from 1990 to 2021, assessed sociodemographic index (SDI)-related patterns, and projected trends to 2041 with ARIMA models. In 2021, these four IMSDs accounted for more than 220 million prevalent cases and over 14 million DALYs worldwide; AV contributed the largest incidence and prevalence burdens, whereas AD accounted for the greatest DALY burden. Age-standardized rates declined slightly for AD and AA but increased for Pso and AV. ASIR correlated positively with SDI for AD, Pso, and AA. Forecasts suggested modest increases for Pso and AV, relative stability for AA, and a slight decline for AD, highlighting disease-specific prevention and disability-burden priorities.